Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Retinitis Pigmentosa (Retinitis) Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Retinitis Pigmentosa (Retinitis) Overview | 13 | 1 |
| Pipeline Products for Retinitis Pigmentosa (Retinitis) Comparative Analysis | 14 | 1 |
| Retinitis Pigmentosa (Retinitis) Therapeutics under Development by Companies | 15 | 2 |
| Retinitis Pigmentosa (Retinitis) Therapeutics under Investigation by Universities/Institutes | 17 | 1 |
| Retinitis Pigmentosa (Retinitis) Pipeline Products Glance | 18 | 3 |
| Late Stage Products | 18 | 1 |
| Clinical Stage Products | 19 | 1 |
| Early Stage Products | 20 | 1 |
| Retinitis Pigmentosa (Retinitis) Products under Development by Companies | 21 | 3 |
| Retinitis Pigmentosa (Retinitis) Products under Investigation by Universities/Institutes | 24 | 1 |
| Retinitis Pigmentosa (Retinitis) Companies Involved in Therapeutics Development | 25 | 30 |
| Acucela Inc. | 25 | 1 |
| Amarantus Bioscience Holdings, Inc. | 26 | 1 |
| Amgen Inc. | 27 | 1 |
| Applied Genetic Technologies Corporation | 28 | 1 |
| Asklepios BioPharmaceutical, Inc. | 29 | 1 |
| Astellas Pharma Inc. | 30 | 1 |
| Caladrius Biosciences, Inc. | 31 | 1 |
| Dompe Farmaceutici S.p.A. | 32 | 1 |
| Genable Technologies Limited | 33 | 1 |
| Genethon | 34 | 1 |
| GenSight Biologics S.A. | 35 | 1 |
| Grupo Ferrer Internacional, S.A. | 36 | 1 |
| ID Pharma Co., Ltd. | 37 | 1 |
| InFlectis BioScience | 38 | 1 |
| International Stem Cell Corporation | 39 | 1 |
| Ionis Pharmaceuticals, Inc. | 40 | 1 |
| M's Science Corporation | 41 | 1 |
| Mimetogen Pharmaceuticals Inc. | 42 | 1 |
| Nanovector s.r.l. | 43 | 1 |
| Orphagen Pharmaceuticals, Inc. | 44 | 1 |
| QLT Inc. | 45 | 1 |
| RegenxBio Inc. | 46 | 1 |
| ReNeuron Group Plc | 47 | 1 |
| SanBio, Inc. | 48 | 1 |
| Sanofi | 49 | 1 |
| Shire Plc | 50 | 1 |
| Spark Therapeutics, Inc. | 51 | 1 |
| Staidson (Beijing) Biopharmaceuticals Co., Ltd. | 52 | 1 |
| Sucampo Pharmaceuticals, Inc. | 53 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 54 | 1 |
| Retinitis Pigmentosa (Retinitis) Therapeutics Assessment | 55 | 9 |
| Assessment by Monotherapy Products | 55 | 1 |
| Assessment by Target | 56 | 2 |
| Assessment by Mechanism of Action | 58 | 2 |
| Assessment by Route of Administration | 60 | 2 |
| Assessment by Molecule Type | 62 | 2 |
| Drug Profiles | 64 | 74 |
| alvespimycin hydrochloride - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| AMRS-001 - Drug Profile | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 3 |
| Antibodies to Antagonize IL-6 for Retinitis - Drug Profile | 68 | 1 |
| Product Description | 68 | 1 |
| Mechanism of Action | 68 | 1 |
| R&D Progress | 68 | 1 |
| BNP-RP - Drug Profile | 69 | 1 |
| Product Description | 69 | 1 |
| Mechanism of Action | 69 | 1 |
| R&D Progress | 69 | 1 |
| CB-11 - Drug Profile | 70 | 1 |
| Product Description | 70 | 1 |
| Mechanism of Action | 70 | 1 |
| R&D Progress | 70 | 1 |
| Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile | 71 | 1 |
| Product Description | 71 | 1 |
| Mechanism of Action | 71 | 1 |
| R&D Progress | 71 | 1 |
| cutamesine - Drug Profile | 72 | 1 |
| Product Description | 72 | 1 |
| Mechanism of Action | 72 | 1 |
| R&D Progress | 72 | 2 |
| ECL-1 - Drug Profile | 74 | 1 |
| Product Description | 74 | 1 |
| Mechanism of Action | 74 | 1 |
| R&D Progress | 74 | 1 |
| emixustat hydrochloride - Drug Profile | 75 | 1 |
| Product Description | 75 | 1 |
| Mechanism of Action | 75 | 1 |
| R&D Progress | 75 | 2 |
| FAB-111 - Drug Profile | 77 | 1 |
| Product Description | 77 | 1 |
| Mechanism of Action | 77 | 1 |
| R&D Progress | 77 | 1 |
| Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile | 78 | 1 |
| Product Description | 78 | 1 |
| Mechanism of Action | 78 | 1 |
| R&D Progress | 78 | 1 |
| Gene Therapy for Ocular Diseases - Drug Profile | 79 | 1 |
| Product Description | 79 | 1 |
| Mechanism of Action | 79 | 1 |
| R&D Progress | 79 | 1 |
| Gene Therapy for Retinitis Pigmentosa - Drug Profile | 80 | 1 |
| Product Description | 80 | 1 |
| Mechanism of Action | 80 | 1 |
| R&D Progress | 80 | 1 |
| Gene Therapy for Retinitis Pigmentosa - Drug Profile | 81 | 1 |
| Product Description | 81 | 1 |
| Mechanism of Action | 81 | 1 |
| R&D Progress | 81 | 1 |
| Gene Therapy for Retinitis Pigmentosa - Drug Profile | 82 | 1 |
| Product Description | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| R&D Progress | 82 | 1 |
| Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile | 83 | 1 |
| Product Description | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| R&D Progress | 83 | 1 |
| Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile | 84 | 1 |
| Product Description | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| R&D Progress | 84 | 1 |
| Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile | 85 | 1 |
| Product Description | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| R&D Progress | 85 | 1 |
| Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile | 86 | 1 |
| Product Description | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| R&D Progress | 86 | 1 |
| Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile | 87 | 1 |
| Product Description | 87 | 1 |
| Mechanism of Action | 87 | 1 |
| R&D Progress | 87 | 1 |
| Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile | 88 | 1 |
| Product Description | 88 | 1 |
| Mechanism of Action | 88 | 1 |
| R&D Progress | 88 | 1 |
| Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| R&D Progress | 89 | 1 |
| GS-030 - Drug Profile | 90 | 1 |
| Product Description | 90 | 1 |
| Mechanism of Action | 90 | 1 |
| R&D Progress | 90 | 2 |
| GT-038 - Drug Profile | 92 | 1 |
| Product Description | 92 | 1 |
| Mechanism of Action | 92 | 1 |
| R&D Progress | 92 | 2 |
| HORAPDE-6B - Drug Profile | 94 | 1 |
| Product Description | 94 | 1 |
| Mechanism of Action | 94 | 1 |
| R&D Progress | 94 | 1 |
| IFB-088 - Drug Profile | 95 | 1 |
| Product Description | 95 | 1 |
| Mechanism of Action | 95 | 1 |
| R&D Progress | 95 | 1 |
| ISIS-RHO2.5Rx - Drug Profile | 96 | 1 |
| Product Description | 96 | 1 |
| Mechanism of Action | 96 | 1 |
| R&D Progress | 96 | 1 |
| KIRA-6 - Drug Profile | 97 | 1 |
| Product Description | 97 | 1 |
| Mechanism of Action | 97 | 1 |
| R&D Progress | 97 | 1 |
| LPDF-003 - Drug Profile | 98 | 1 |
| Product Description | 98 | 1 |
| Mechanism of Action | 98 | 1 |
| R&D Progress | 98 | 1 |
| myriocin - Drug Profile | 99 | 1 |
| Product Description | 99 | 1 |
| Mechanism of Action | 99 | 1 |
| R&D Progress | 99 | 1 |
| N-acetyl cysteine amide - Drug Profile | 100 | 1 |
| Product Description | 100 | 1 |
| Mechanism of Action | 100 | 1 |
| R&D Progress | 100 | 1 |
| NT-501 - Drug Profile | 101 | 1 |
| Product Description | 101 | 1 |
| Mechanism of Action | 101 | 1 |
| R&D Progress | 101 | 3 |
| OCU-100 - Drug Profile | 104 | 1 |
| Product Description | 104 | 1 |
| Mechanism of Action | 104 | 1 |
| R&D Progress | 104 | 1 |
| Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile | 105 | 1 |
| Product Description | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| R&D Progress | 105 | 2 |
| ReN-003 - Drug Profile | 107 | 1 |
| Product Description | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| R&D Progress | 107 | 2 |
| RGX-321 - Drug Profile | 109 | 1 |
| Product Description | 109 | 1 |
| Mechanism of Action | 109 | 1 |
| R&D Progress | 109 | 2 |
| RST-001 - Drug Profile | 111 | 1 |
| Product Description | 111 | 1 |
| Mechanism of Action | 111 | 1 |
| R&D Progress | 111 | 1 |
| SAR-421869 - Drug Profile | 112 | 1 |
| Product Description | 112 | 1 |
| Mechanism of Action | 112 | 1 |
| R&D Progress | 112 | 2 |
| SB-623 - Drug Profile | 114 | 1 |
| Product Description | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| R&D Progress | 114 | 2 |
| SHP-630 - Drug Profile | 116 | 1 |
| Product Description | 116 | 1 |
| Mechanism of Action | 116 | 1 |
| R&D Progress | 116 | 1 |
| Small Molecule for Retinitis Pigmentosa - Drug Profile | 117 | 1 |
| Product Description | 117 | 1 |
| Mechanism of Action | 117 | 1 |
| R&D Progress | 117 | 1 |
| Small Molecule for Retinitis Pigmentosa - Drug Profile | 118 | 1 |
| Product Description | 118 | 1 |
| Mechanism of Action | 118 | 1 |
| R&D Progress | 118 | 1 |
| Small Molecules for CNS Disorders and Ophthalmology - Drug Profile | 119 | 1 |
| Product Description | 119 | 1 |
| Mechanism of Action | 119 | 1 |
| R&D Progress | 119 | 1 |
| Small Molecules for Retinitis Pigmentosa - Drug Profile | 120 | 1 |
| Product Description | 120 | 1 |
| Mechanism of Action | 120 | 1 |
| R&D Progress | 120 | 1 |
| Small Molecules for Retinitis Pigmentosa - Drug Profile | 121 | 1 |
| Product Description | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| R&D Progress | 121 | 1 |
| Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile | 122 | 1 |
| Product Description | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| R&D Progress | 122 | 1 |
| STC-1 - Drug Profile | 123 | 1 |
| Product Description | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| R&D Progress | 123 | 1 |
| Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile | 124 | 1 |
| Product Description | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| R&D Progress | 124 | 2 |
| Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile | 126 | 1 |
| Product Description | 126 | 1 |
| Mechanism of Action | 126 | 1 |